Last reviewed · How we verify

PerioChip ®

Dexcel Pharma Technologies Ltd. · FDA-approved active Small molecule

PerioChip releases chlorhexidine directly into periodontal pockets to reduce bacterial infection and inflammation in periodontal disease.

PerioChip releases chlorhexidine directly into periodontal pockets to reduce bacterial infection and inflammation in periodontal disease. Used for Adjunctive treatment of adult periodontitis.

At a glance

Generic namePerioChip ®
SponsorDexcel Pharma Technologies Ltd.
Drug classLocal antimicrobial agent
TargetBacterial cell membranes (chlorhexidine non-specific antimicrobial)
ModalitySmall molecule
Therapeutic areaDentistry / Periodontics
PhaseFDA-approved

Mechanism of action

PerioChip is a biodegradable chip containing chlorhexidine gluconate that is inserted into periodontal pockets where it provides sustained local delivery of the antimicrobial agent over several days. The chlorhexidine kills or inhibits periodontal pathogens, reducing pocket depth and bleeding on probing. This localized delivery approach achieves high drug concentrations at the site of infection while minimizing systemic exposure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results